Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: boomertree2 who wrote (12077)	6/12/2013 6:08:18 PM
From: jm2i123	Read Replies (2) \| Respond to of 13111

Don't you understand that a phase 3 trial approval most always means signing a licensing deal in this market?...also because the drug is cheap to produce and if it's SPA, a few millions will do (btw check the top biotech ceo's out there...it still is below..). Game changer.

To: boomertree2 who wrote (12077)	6/12/2013 8:20:28 PM
From: dirkdiggler	2 Recommendations Recommended By boomertree2 Pogeu Mahone Respond to of 13111

Unfortunately, this is what I have read. So, let's just say I'm a big Pharma Co. and I want to buy PVCT. I can just wait them out and get a sweet heart deal. Three year since PII ended and no PIII start isn't helping their position. Thay only ones making out in this stock is management.